10 September 2026
INBRX-106/Pembrolizumab Shows Efficacy in First-Line HNSCC
Source: Targeted Oncology.
The Phase II HexAgon clinical trial investigated INBRX-106, an experimental immune-stimulating treatment, alongside pembrolizumab.
Results showed:
Treatment
Tumour response rate
INBRX-106 + pembrolizumab
48.3%
Pembrolizumab alone
26.5%
The results were particularly interesting for HPV-positive cancers:
80% response rate with the combination.
30% achieved complete responses.
Median progression-free survival was 9.6 months, compared with 4.9 months for pembrolizumab alone.
The treatment is designed to stimulate OX40, a protein involved in activating immune cells.
Further development is planned, including additional research involving HPV-positive oropharyngeal cancer.
Why this matters: Researchers are exploring ways to make existing immunotherapies work more effectively by stimulating different parts of the immune system.
